Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report)’s stock price traded down 1.9% during trading on Thursday . The stock traded as low as $7.75 and last traded at $7.75. Approximately 2,850 shares changed hands during mid-day trading, a decline of 74% from the average session volume of 11,030 shares. The stock had previously closed at $7.90.
Wall Street Analyst Weigh In
Separately, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Idorsia in a report on Monday, August 3rd. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.
View Our Latest Analysis on IDRSF
Idorsia Price Performance
Idorsia Company Profile
Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.
Further Reading
- Five stocks we like better than Idorsia
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
- AirJoule Technologies: Short Squeeze Setup Amid Rising Risks
- MarketBeat Week in Review – 08/10 – 08/14
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
